News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The supply of these goods is set to commence within the first quarter of FY26
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Strengthening capabilities in Peptide Therapeutics and CDMO services
Subscribe To Our Newsletter & Stay Updated
